Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

Mobocertinib (TAK‐788) is an investigational oral tyrosine kinase inhibitor targeting epidermal growth factor receptor and human epidermal growth factor 2. A phase 1 open‐label, 2‐period, fixed‐sequence, 2‐part study (NCT03928327) characterized effects of a strong CYP3A4 inhibitor (itraconazole) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Steven, Jin, Shu, Griffin, Celina, Feng, Zhongling, Lin, Jianchang, Venkatakrishnan, Karthik, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453750/
https://www.ncbi.nlm.nih.gov/pubmed/34145979
http://dx.doi.org/10.1002/cpdd.967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453750/
https://www.ncbi.nlm.nih.gov/pubmed/34145979
http://dx.doi.org/10.1002/cpdd.967

Ejemplares similares